About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Maternal and Fetal Medicine Research Group has been recognized by AGAUR as a consolidated research group. It is a multidisciplinary team which integrates different knowledge areas in basic and clinical research. Basic research aims to identify new diagnostic and therapeutic tools in maternal and fetal pathologies, while clinical research intends to apply these tools in clinical practice.
The group has different investigation areas:
IP: -
IP: Elena Carreras Moratonas
IP: Manel Mendoza Cobaleda, Pablo García Manau
IP: Maria del Mar Goya Canino Collaborators: Erika Bonacina, Ester Del Barco Martínez Funding agency: Instituto de Salud Carlos III Funding: 29645 Reference: PI19/00287 Duration: 01/01/2020 - 30/06/2024
IP: Francina Munell Casadesus Collaborators: Laura Costa Comellas, Elena Antima Martinez Saez, Maite Avilés García, David Gómez Andrés Funding agency: Instituto de Salud Carlos III Funding: 73205 Reference: AC19/00048 Duration: 01/01/2020 - 31/12/2023
IP: Elena Carreras Moratonas Collaborators: Itziar Garcia Ruiz, Erika Bonacina, Joana Ramis Garcia Funding agency: Instituto de Salud Carlos III Funding: 111320 Reference: PI20/00606 Duration: 01/01/2021 - 30/06/2025
IP: Nerea Maiz Elizaran Collaborators: Ana Lain Fernandez, Margarita Codinach Creus, Silvia Arévalo Martínez, Pablo García Manau, Paula Garcia Aguilar, Susana Manrique Muñoz, Manuel López Paredes, Ester Del Barco Martínez, Erika Bonacina Funding agency: Instituto de Salud Carlos III Funding: 135520 Reference: PI20/00421 Duration: 01/01/2021 - 30/06/2025
Vall d’Hebron is part of the Consorcio INTERCOVID, which has analyzed over 6,500 pregnancies in 18 countries and observed a significant reduction in the risk of preeclampsia associated with vaccination.
Vall d’Hebron has taken part in a clinical trial whose results show improvements in endometrial regeneration and reproductive outcomes in patients with Asherman syndrome who had not responded to previous surgery.
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
